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Abstract
Background: The majority of commensal gastrointestinal bacteria used as probiotics are highly
adapted to the specialised environment of the large bowel. However, unlike pathogenic bacteria;
they are often inadequately equipped to endure the physicochemical stresses of gastrointestinal
(GI) delivery in the host. Herein we outline a patho-biotechnology strategy to improve gastric
delivery and host adaptation of a probiotic strain Bifidobacterium breve UCC2003 and the generally
regarded as safe (GRAS) organism Lactococcus lactis NZ9000.
Results: In vitro bile tolerance of both strains was significantly enhanced (P < 0.001), following
heterologous expression of the Listeria monocytogenes bile resistance mechanism BilE. Strains
harbouring bilE were also recovered at significantly higher levels (P < 0.001), than control strains
from the faeces and intestines of mice (n = 5), following oral inoculation. Furthermore, a B. breve
strain expressing bilE demonstrated increased efficacy relative to the wild-type strain in reducing
oral L. monocytogenes infection in mice.
Conclusion: Collectively the data indicates that bile tolerance can be enhanced in Bifidobacterium
and Lactococcus species through rational genetic manipulation and that this can significantly improve
delivery to and colonisation of the GI tract.
Background
Probiotics, defined by a working group of the Interna-
tional Life Sciences Institute Europe (ILSI Europe) as "a
viable microbial food supplement, which beneficially
influences the health of the host" [1], have become the
focus of considerable research interest in recent years [2-
4]. Live probiotic organisms (including Bifidobacterium
spp.) have been shown to reduce the symptoms of inflam-
matory conditions such as inflammatory bowel disease
(IBD) and irritable bowel syndrome (IBS) [5]. This is
believed to occur via the localized stimulation of anti-
inflammatory cytokines (including IL-10) as a result of
beneficial alterations to the microbiota [6]. Proof of prin-
ciple and efficacy has been demonstrated with the inert
food organism Lactococcus lactis which has been engi-
neered to secrete IL-10 locally within the gut in murine
models of IBD in order to alleviate symptoms of gastroin-
testinal inflammation [7]. However, despite their obvious
clinical potential, these strains are often poorly adapted to
conditions encountered in the upper gastrointestinal tract
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and delivery of viable organisms from the mouth to the
large intestine remains a major hurdle to their use in
human therapies [8,9].
Listeria monocytogenes is a Gram-positive intracellular
foodborne pathogen capable of withstanding a variety of
hostile environmental conditions, including the numer-
ous stresses encountered during the production, prepara-
tion, and storage of food [10]. Following consumption L.
monocytogenes effectively survives the extreme conditions
encountered during gastric passage, including the low pH
of the stomach, low oxygen content and elevated osmolar-
ity and bile salts associated with the upper small intestine
[10,11]. Bile in particular represents a key challenge to
bacteria that survive and transit the stomach and enter the
small intestine. Listeria has been isolated from the human
gallbladder [12,13], indicating an inherent ability to tol-
erate high concentrations of bile. Previously Sleator et al.,
[14], identified a novel bile resistance mechanism desig-
nated BilE, which when disrupted resulted in a bile sensi-
tive phenotype. BilE, which functions by excluding bile
from the cell, has also been shown to facilitate improved
gastrointestinal transit in mouse models of infection and
as such contributes to the gastrointestinal phase of L.
monocytogenes infection. Interestingly, not many homo-
logues of the bilE operon have been identified in any of
the genomes of the probiotic or commensal organisms
sequenced to date. The only homology found was busA
(opuA) of L. lactis, which encodes a glycine betaine uptake
system. This system is osmotically inducible as was
believed to be the case with bilE. However, Sleator et al,
(2005) have shown that bilE does not play a role in osmo-
tolerance, but in fact a major role in bile tolerance.
Herein, we demonstrate that heterologous expression of
the listerial bile resistance mechanism BilE improves bile
resistance in vitro as well as enhancing gastrointestinal per-
sistence and clinical efficacy of the probiotic strain B. breve
UCC2003. Furthermore, expression in L. lactis enhanced
bile tolerance and in vivo survival and may have applica-
tions in targeted vaccine or drug delivery by this organism.
Methods
Bacterial strains, plasmids, and culture conditions
The strains and plasmids used in this study are listed in
Table 1. Escherichia coli strain DH10B (Invitrogen, Paisley,
United Kingdom) used as a cloning host, was grown aer-
obically at 37°C in Luria-Bertani (LB) medium [15].Bifi-
dobacterium breve UCC2003, a human commensal
originally isolated from an infant nursling stool, was
anaerobically cultured in Reinforced Clostridial medium
(Oxoid) or de Man, Rogosa and Sharpe medium (MRS)
supplemented with 0.05% (wt/vol) l-cysteine HCl. Anaer-
obic conditions were maintained using an Anaerocult
oxygen-depleting system (Merck, Darmstadt, Germany)
in an anaerobic chamber. Lactococcus lactis NZ9000 strain
was grown in M17 medium supplemented with 0.5% (wt/
vol) glucose (GM17) at 30°C. L. monocytogenes EGD-e
[16] was cultured aerobically at 37°C in brain heart infu-
sion (BHI) medium. Oxoid Ltd., (Basingstoke, Hamp-
shire, United Kingdom) supplied all growth media. For
solid media, 1.5% agar was added. When appropriate,
antibiotics were added at the following final concentra-
tions: for E. coli, B. breve, and L. lactis, chloramphenicol 15
μg ml-1, 4 μg ml-1 and 5 μg ml-1 respectively. Porcine bile
(B-8631) was obtained from Sigma (Sigma Chemical Co.
Ltd., Poole, United Kingdom). The required quantity of
bile was solubilised in water and autoclaved.
Genetic manipulations
Plasmid DNA was isolated from E. coli using a QIAprep
Spin Miniprep kit according to the manufacturer's instruc-
tions (QIAGEN, Crawley, United Kingdom). Genomic
DNA was isolated from L. monocytogenes EGD-e using a
Genelute bacterial genomic DNA kit (Sigma, Steinheim,
Germany) as recommended by the manufacturer. Trans-
formation of L. lactis was achieved according to the proto-
col of de Vos et al. [17]. Standard procedures were used for
DNA manipulation in E. coli [15]. Restriction endonucle-
ases (Roche Diagnostics, Mannheim, Germany), T4 DNA
ligase (Roche), and 2× PCR mixture (Promega, Madison,
WI) were used as recommended by the manufacturers.
Oligonucleotide primers were synthesized by Sigma
Genosys (Haverhill, United Kingdom). PCR products
required for cloning were generated with KOD hot-start
high-fidelity DNA polymerase (Merck, Nottingham,
United Kingdom) using 10 ng L. monocytogenes genomic
DNA.
Plasmid construction
Analysis of the bilE  operon in L. monocytogenes EGD-e
(accession number NC_003210) uncovered the presence
of two Open Reading Frames (ORFs) bilEA  (accession
number NP_464946 and GI number GI:16803461) and
bilEB (accession number is NP_464947.1 and GI number
is GI:16803462), oriented in the same direction and over-
lapping by five nucleotides. PCR primers with incorpo-
rated  XbaI (5'-CATTCTAGAGTTTGTAAGTTATT-3') and
PstI (5'-CAAATTCTTTGTTGAATTCCTGCAGATAT-3')
restriction enzyme sites (underlined) were used to
amplify the complete bilE operon from the chromosome
of L. monocytogenes EGD-e. The resultant 2.9 kb PCR prod-
uct was digested with XbaI and PstI and subsequently
ligated into similarly digested pNZ8048 using T4 DNA
ligase (Roche Diagnostics). The resultant plasmid, con-
taining bilE under the transcriptional control of its own
promoter, was designated pNZ8048-bilE+ as in Table 1.
Both pNZ8048-bilE+ and pNZ8048-bilE- (control) initially
introduced into E. coli DH10B as a cloning host. Plasmid
DNA was extracted from successful transformants, wasBMC Microbiology 2008, 8:176 http://www.biomedcentral.com/1471-2180/8/176
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sequenced and subsequently transformed into the bifido-
bacterial strain UCC2003 and lactococcal strain NZ9000
yielding UCC2003-bilE+and NZ9000-bilE+  respectively.
Strains harbouring pNZ8048, which was used as a nega-
tive control, were named UCC2003-bilE- and NZ9000-
bilE- respectively. Chloramphenicol was added to plates as
a selective marker.
Electroporation
Electroporation of plasmid DNA into E. coli and L. lactis
was performed essentially as previously described. Elec-
tro-transformation of B. breve with plasmid DNA was per-
formed as described by MacConaill et al. [18]. Essentially,
mid-logarithmic-phase cells (optical density at 600 nm,
0.5 to 0.6) were chilled on ice for 20 min, followed by
centrifugation. The cell pellet was washed twice and resus-
pended in 0.5 M sucrose-1 mM citrate buffer (pH 5.8).
Cells were incubated on ice for 10 min, and this was fol-
lowed by electro-transformation with a Bio-Rad Gene
Pulser II apparatus under the following conditions: 25 μF,
200 Ω and 2.0 kV cm-1. Modified Rogosa medium was
added to the cells, and the mixture was incubated anaero-
bically at 37°C for 2.5 hr prior to plating onto RCA (Rein-
forced Clostridial agar) containing the appropriate
antibiotic.
Plasmid stability study
B. breve UCC2003 colonies containing pNZ8048-bilE+
and pNZ8048-bilE- and L. lactis NZ9000 colonies contain-
ing pNZ8048-bilE+and pNZ8048-bilE- were first cultured
in MRS broth containing 4 μg ml-1 chloramphenicol and
GM17 broth with 5 μg ml-1 respectively. Cells were then
sub-cultured in fresh MRS and GM17 broth without anti-
biotic selection every 24 hrs for a total of 50 generations.
Vector segregation stability was monitored by plating iso-
lated colonies every 48 hrs. 100 colonies were replica
plated onto MRSCm4 and GM17Cm5. B. breve was incu-
bated anaerobically at 37°C and L. lactis incubated aero-
bically at 30°C for 24 hrs. The percentage of loss of the
test plasmid in the population was then calculated.
Transcriptional analysis
Total RNA was isolated from B. breve UCC2003 and L. lac-
tis NZ9000 cells grown to an optical density at 600 nm
Table 1: Bacterial strains, plasmids and primers used in this study
Strain or plasmid Relevant properties* Source or Reference
Strains
B. breve
UCC2003 Wild-type parent strain UCC culture collection
UCC2003-bilE- UCC2003 containing the cloning vector pNZ8048 This study
UCC2003-bilE+ UCC2003 containing the cloning vector pNZ8048-bilE+ This study
L. lactis subsp. Cremoris
NZ9000 L. lactis subsp. cremoris MG1363 carrying nisRK on the chromosome 10.
NZ9000-bilE- NZ9000 containing the cloning vector pNZ8048 This study
NZ9000-bilE+ NZ9000 containing the cloning vector pNZ8048-bilE+ This study
E. coli
DH10B Cloning host Invitrogen
L. monocytogenes
EGD-e Wild-type of serotype 1/2a for which the genome sequence is available. UCC culture collection
Plasmid
pNZ8048 *Cmr, low copy number plasmid. 37.
pNZ8048-bile+ *Cmr, low copy number plasmid, harbouring bilE under the control of the native listerial 
promoter.
This study
Primers Sequence 5'-3'
BilEF CATTCTAGAGTTTGTAAGTTATT
BilER CAAATTCTTTGTTGAATTCCTGCAGATAT
Bif16SF CCGGATGCTCCATCACAC
Bif16SR ACAAAGTGCCTTGCTCCCT
Lac16SF TGGCTCAGGACGAACGCTGGCGGC
Lac16SF CCTACTGCTGCCTCCCGTAGGAGT
RT-PCRF GCTTGATTCCACTGACAACTGG
RT-PCRR CTTGTGGTGTTGCTACTTGGACBMC Microbiology 2008, 8:176 http://www.biomedcentral.com/1471-2180/8/176
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(OD600) of 0.6 using the macaloid acid method as
described by Ventura et al. (38) and then treated with
DNase (Roche). Reverse transcription for cDNA was
mediated by thermostable Superscript reverse tran-
scriptase (Invitrogen) using 10–20 μg RNA as a template
in a 30 μl reaction mixture containing 6 μl 5× Superscript
III buffer, 2 ng of random primers p(dN)6, 3 μl 100 mM
dithiothreitol, 1.2 μl of deoxynucleoside triphosphate
mix and the Superscript enzyme (Invitrogen, Paisley,
United Kingdom), which was used according the manu-
facturer's instructions to produce cDNA. The cDNA gener-
ated was used as a template for reverse transcription (RT)-
PCRs performed with primers RT-PCRF and RT-PCRR. In
all cases, control PCR reactions were used to ensure the
complete removal of DNA from RNA preparations prior
to reverse transcription.
Resistance to Bile
To determine the ability of strains to survive at sub-lethal
bile concentrations, the B. breve and L. lactis cultures were
grown to stationary phase and were subsequently inocu-
lated (3%) into MRS and GM17 broth containing 1% (wt/
vol) porcine bile. Viable cell counts were performed at
intervals by serial dilution in one-quarter-strength
Ringer's solution and plating onto RCMCm4 or
GM17Cm5 respectively.
Animal studies
Female BALB/c (Harlan UK Ltd. Bicester, Oxon, United
Kingdom) mice (aged 8–12 weeks) were used for in vivo
studies. Mice were housed in pathogen free conditions in
a dedicated facility and were fed standard laboratory feed
and water ad libtium. All animal procedures were per-
formed according to the University's ethical guidelines.
Inoculations were carried out essentially as described by
Sleator et al., [19].
Probiotic Gastrointestinal Persistence studies
Prior to commencement of the trials (outlined in Fig. 1),
the absence of background microflora in murine faecal
pellets was confirmed by plating onto the two selective
agars containing antibiotic. For the study five mice were
used per bacterial strain. Each mouse was administered 20
μL of bifidobacteria or lactococcus (2 × 109 CFU per mouse)
by oral pipette for 3 consecutive days, leading to coloniza-
tion of the gastrointestinal tract. Gastrointestinal persist-
ence of both strains was tracked by measuring the
excretion of viable B. breve in fresh faecal samples col-
lected for 19 days post feeding and L. lactis for 3 days.
Fresh samples were weighed, homogenized in PBS
(Gibco, Paisley, Scotland), diluted and plated onto RCA
or GM17 with the appropriate level of chloramphenicol.
At days nineteen (B. breve) and four (L. lactis) post dosing
the mice were sacrificed by cervical dislocation, intestines
and caeca were excised. The organs were homoginized in
5 mls PBS, serially diluted and the bifidobacterial and lac-
tococcal numbers in the intestines and caeca of dosed ani-
mals were determined by spread-plating homogenates
onto RCACm4 and GM17Cm5 plates.
Schematic of the design protocol Figure 1
Schematic of the design protocol.BMC Microbiology 2008, 8:176 http://www.biomedcentral.com/1471-2180/8/176
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Listeria challenge
Animal feeding trials were performed to determine
whether the probiotic strains harbouring pNZ8048-bilE+
conferred protection against subsequent infection with L.
monocytogenes. BALB/c mice were fed Bifidobacteria (2 ×
109 CFU per mouse) by oral pipette for 3 consecutive days
before oral infection with L. monocytogenes EGD-
e::pPL2lux (2 × 1010 CFU per mouse) on day 14. Three
days post infection, the mice were sacrificed by cervical
dislocation, livers and spleens were excised, homogenized
in 5 mls PBS, and serial dilutions were plated onto
BHICm agar, which was followed by overnight incubation
at 37°C. The resulting colonies were used to calculate the
number of bacteria per organ.
Statistical Analysis
Numerical results were expressed as arithmetic means +/-
standard deviations of the means. CFU determinations
were converted to Log10 values, and then the arithmetic
means and standard deviations were calculated. Error bars
in the figures represent standard deviations. Student's t
test was performed to determine the statistical signifi-
cance.
Results
Improving tolerance to porcine bile
The BilE system was amplified from L. monocytogenes and
cloned into the plasmid vector pNZ8048 under the con-
trol of its native promoter. The plasmid was electropo-
rated into both B. breve UCC2003 and L. lactis NZ9000
(see Table 1). To establish the segregational stability of the
pNZ8048 constructs a plasmid stability assay was per-
formed over approximately 50 generations. Both con-
structs (pNZ8048-bilE+ and pNZ8048-bilE-) were capable
of replication on B. breve UCC2003 and were found to
exhibit considerable stability (98.55 +/- 0.63%) in the
absence of selective pressure (data not shown). The con-
structs were also capable of replication in L. lactis NZ9000
and were found to exhibit considerable stability (100%)
in the absence of selective pressure. Proof that the operon
was heterologously expressed in both bacterial strains was
evident as a single mRNA transcript was obtained by
reverse transcription polymerase chain reaction (RT-PCR)
analysis (Fig. 2) also in vitro studies showing increased
bile resistance supports this by indicating that the bile
resistance locus was functional. Due to difficulty in
obtaining human bile; porcine bile was used to examine
the bile tolerance of B. breve bilE+ and L. lactis bilE+. Por-
cine bile is considered an acceptable substitute because
the salt/cholesterol, phospholipids/cholesterol and gly-
cine/taurine ratios resemble the composition of human
bile [20]. We utilised levels of porcine bile (1% w/v) that
were lethal for the bacterial species examined and are
likely to approximate in vivo levels in regions of the small
intestine (e.g. the duodenum) where bile is most concen-
trated [20]. It was observed that the presence of bilE ren-
dered the engineered L. lactis strain considerably more
resistant to the initial kill by porcine bile relative to the
wild-type (empty pNZ8048). The engineered strain dem-
onstrated a 2.5-log enhanced resistance to bile over the 20
(A) Flow diagram for the expression of the bilEAB operon, indicating the listerial bilE operon (B) RT-PCR analysis of the heter- ologous expression of the bilEAB bile resistance loci in B. breve and L. lactis (a) Control PCRS using cDNA template and the 16S  RNA specific primers Bif16SF, Bif16SR, Lac16SF and Lac16SR to confirm the presence of the correct template Figure 2
(A) Flow diagram for the expression of the bilEAB operon, indicating the listerial bilE operon (B) RT-PCR analysis 
of the heterologous expression of the bilEAB bile resistance loci in B. breve and L. lactis (a) Control PCRS using cDNA template 
and the 16S RNA specific primers Bif16SF, Bif16SR, Lac16SF and Lac16SR to confirm the presence of the correct template. (b) 
bilE specific primers RTPCR F and RTPCR R amplify a 500 bp fragment from both UCC3003-bilE+ and NZ9000-bilE+ cDNA, 
while as expected no product was obtained when the cDNA of the control strains UCC3003-bilE- and NZ9000-bilE- were used 
as template.BMC Microbiology 2008, 8:176 http://www.biomedcentral.com/1471-2180/8/176
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minute course of the kill curve (Fig. 3A). In contrast whilst
B. breve bilE+ demonstrated a similar initial kill to the wild-
type (after 5 minutes) the engineered strain was subse-
quently better equipped to survive in porcine bile. At 15
minutes and 20 minutes post-exposure the B. breve bilE+
strain demonstrated 2.5 log enhanced survival (Fig. 3B).
Similar results were seen in experiments carried out using
bovine bile (oxgall) (data not shown).
Gastrointestinal Persistence of L. lactis BilE+ and B. breve 
BilE+
In order to test whether the elevated bile tolerance of the
engineered strains would influence survival in the GI tract,
we utilized a mouse model to follow survival in vivo, using
an approach previously outlined by Sheehan et al. [21]. To
facilitate gastrointestinal colonization by B. breve and L.
lactis strains, each BALB/c mouse was orally administered
2 × 109 CFU for three successive days. Gut persistence was
monitored by faecal carriage with samples taken every 24
h for 3 days in the case of L. lactis and every 48 h for 19
days for B. breve.
L. lactis BilE+ demonstrated significantly enhanced in vivo
survival relative to the control over the course of the study
(Fig. 4). Both BilE+ and BilE- strains were detectable in fae-
ces at approximately the same levels at 24 hours post inoc-
ulation. However, the wild-type was undetectable at day 2
post-inoculation. This reflects the naturally poor rate of
gastrointestinal survival for L. lactis also observed in other
studies [22]. In contrast L. lactis BilE+was detectable at
high levels in murine faeces at days 2 and 3 post-inocula-
tion. Neither BilE+ nor BilE- strains engineered L. lactis
were detectable at day 4 post-inoculation. These data
demonstrate significant (P < 0.001) enhancement of gas-
trointestinal survival of L. lactis through rational biologi-
cal engineering.
Survival of stationary phase Lactococcus lactis (A) and Bifido- bacterium breve (B) in 1% porcine bile Figure 3
Survival of stationary phase Lactococcus lactis (A) and 
Bifidobacterium breve (B) in 1% porcine bile. pNZ8048-
bilE+ (black circles) and pNZ8048-bilE- (white circles). Over-
night cultures were inoculated (3%) into GM17 and MRS 
broth containing 1% porcine bile. Viable cell counts were 
performed by serial dilution in one-quarter strength Ringer's 
solution followed by plating onto GM17Cm5 or RCMCm4 
respectively. **; P < 0.001 compared with the control. Stand-
ard deviations of triplicate results are represented by error 
bars.
Effect of bilE on gastrointestinal persistence over 3 days Figure 4
Effect of bilE on gastrointestinal persistence over 3 
days.Lactococcus lactis bilE+ (black circles) and Lactococcus lac-
tis bilE- (white circles) were used for peroral inoculation of 
female BALB/c mice (n = 5). Lactococcus lactis counts were 
determined in stools at 24, 48 and 72 hour intervals. Error 
bars represent the standard deviation of five animals. **; P < 
0.001 compared with the control.BMC Microbiology 2008, 8:176 http://www.biomedcentral.com/1471-2180/8/176
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B. breve UCC2003 transiently colonized the murine GI
tract at levels of approximately 107 CFU/g faeces irrespec-
tive of the presence of BilE. However, at day 12 post inoc-
ulation a significant (P < 0.001) difference began to
emerge between the engineered B. breve UCC2003 BilE+
strain and the BilE-, with the BilE+ strain demonstrating
elevated persistence in faeces compared to the wildtype,
which declined significantly (Fig. 5A). At the final day of
the experiment (day 19 post inoculation) the BilE+ strain
persisted at levels of approximately 4.5 × 107 CFU/g faeces
whereas the wild-type had declined to 1 × 105 CFU/g fae-
ces. This is a more substantial difference than that
observed by Sheehan et al. [21] using a similar approach
which involved cloning the BetL osmotolerance locus into
B. breve.
At day 19 mice were examined directly for the presence of
B. breve UCC2003 in the small intestine, caecum and large
intestine (Fig. 5B). We confirmed a 2-log difference
between the BilE+ and wt strains in the small intestine with
the engineered strain present at significantly higher levels.
This finding is important given that this region is associ-
ated with the highest levels of bile in the GI tract [20].
Interestingly Sheehan et al. [21] did not demonstrate
enhanced survival of the BetL+ strain in the small intes-
tine. We also determined significantly enhanced levels of
the engineered strain in the caecum and large intestine (P
< 0.001). Overall, the approximately 2 log increased per-
sistence of the engineered strain in the murine intestine
mirrored the results of the faecal persistence studies.
Effect of engineered BilE+ B. breve on oral Listeria 
challenge
Administration of B. breve UCC2003 has previously been
demonstrated to reduce splenic levels of L. monocytogenes
following oral infection of mice [23]. We hypothesized
that the elevated colonisation of B. breve BilE+ in the small
intestines of mice (Fig. 5) may further enhance this pro-
tective effect since L. monocytogenes invades at this site. To
test this hypothesis we administered mice with either
wild-type or BilE+ B. breve UCC2003 on three consecutive
days and challenged with oral L. monocytogenes infection
at day 14 post-inoculation. At the 14 day time point we
again detected higher levels of the engineered BilE+ strain
relative to the wild-type in mouse faeces (data not
shown). Following oral infection with L. monocytogenes we
determined that oral dosing with the engineered BilE+ B.
breve strain significantly enhanced clearance of L. monocy-
togenes as assessed by pathogen load in the liver (Fig. 6A).
A similar (though not statistically significant) trend was
seen when the numbers of Listeria in the spleens of the
infected mice was determined (Fig. 6B). Although differ-
ences in infectious burden were small the data indicate
improved probiotic efficacy of engineered B. breve.
Discussion and conclusion
Foodborne pathogens are capable of rapid adaptation to
diverse environmental niches associated with survival in
the external environment and transit through the gas-
trointestinal tract of the host [24]. In contrast, the autoch-
thonous gastrointestinal microbiota demonstrates a high
degree of niche-specialisation [25]. This specialisation is
an impediment to the delivery of so-called probiotic
strains to the human GI tract as these strains must survive
gastric acid in the stomach and elevated osmolarity and
bile acids in the small intestine before establishing a pres-
ence in the large bowel [26]. The term 'patho-biotechnol-
(A) Effect of bilE on the gastrointestinal persistence of Bifido- bacterium breve bilE+ (black circles) and Bifidobacterium breve  bilE- (white circles) were used for peroral inoculation of  female BALB/c mice (n = 5) Figure 5
(A) Effect of bilE on the gastrointestinal persistence 
of Bifidobacterium breve bilE+ (black circles) and Bifi-
dobacterium breve bilE- (white circles) were used for 
peroral inoculation of female BALB/c mice (n = 5).Bifi-
dobacterium breve counts were determined in stools at 48 
hour intervals. (B) At day 19 mice were sacrificed and Bifido-
bacterium breve harbouring bilE (black bars) were recovered 
at significantly higher numbers in the intestines and caeca 
than the controls (white). *; P < 0.01, **, P < 0.001.BMC Microbiology 2008, 8:176 http://www.biomedcentral.com/1471-2180/8/176
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ogy' was recently coined to highlight the beneficial
biotechnological uses of molecular systems derived from
pathogens [24,27-29]. This concept was recently applied
to improve the osmotolerance of potential probiotic
strains through rational molecular engineering [21,30].
Here we implement the patho-biotechnology concept to
improve the in vivo and in vitro bile resistance of a poten-
tial probiotic strain, B. breve UCC2003, as well as the food
isolate L. lactis, through cloning and expression of a bile
tolerance system in these organisms.
Bile acids are amphipathic molecules synthesized from
cholesterol that are produced in the liver, stored interdi-
gestively in the gall bladder and released into the duode-
num where their main function is the breakdown of
dietary fats. Bile also plays a vital role in the physiochem-
ical defences of the host through direct degradation of
bacterial membranes [30]. Selection of probiotic strains
for use in humans has typically been based upon intrinsic
acid and bile resistance traits [31]. However, members of
the Lactobacillus and Bifidobacteria spp are known to dem-
onstrate low levels of innate bile tolerance when com-
pared to pathogens such as L. monocytogenes [20]. We
recently described the presence of a novel bile exclusion
system (BilE) in L. monocytogenes which permits the active
exclusion of bile from the cell in a manner similar to multi
drug efflux pumps of Gram negative bacteria such as E.
coli. In Listeria elimination of BilE results in a 5-log reduc-
tion in tolerance of bile in vitro and has a significant
impact upon virulence potential [14]. BilE is not widely
distributed in Gram positive organisms; however homol-
ogy was found with the osmotically inducible busA of L.
lactis. Sleator et al., 2005, showed that bilE is involved in
bile exclusion and not in osmotolerance as previously
believed. Here cloning and expression of BilE in B. breve
and L. lactis resulted in a 2.5 to 3.5-log increased tolerance
of porcine bile. Similarly these engineered strains demon-
strate improved resistance to bovine bile in vitro (data not
shown). These data provide proof of concept that bile tol-
erance in these strains can be significantly enhanced
through rational genetic manipulation.
Wild-type L. lactis survives poorly in the murine GI tract
[22]. However, L. lactis has been proposed as a vehicle for
delivery of oral vaccines and biotherapeutic agents [9].
Indeed, an L. lactis strain engineered to produce human
IL-10 has recently been investigated in human clinical tri-
als for the therapy of Crohn's disease [32]. We show that
L. lactis expressing cloned BilE demonstrates significantly
enhanced survival in the GI tract of mice (as measured in
faeces) relative to the wild-type L. lactis strain. The results
indicate that molecular engineering approaches may have
the potential to enhance the proposed biomedical appli-
cations of L. lactis.
Survival of B. breve in the murine GI tract was also signifi-
cantly enhanced through expression of BilE. The engi-
neered strain was detected at significantly higher levels
than the wild-type in faeces (at day 12) as well as in the
small intestine, caecum and colon of inoculated animals.
Bifidobacterium species are known to only transiently col-
onise the GI tract when administered as a probiotic thera-
peutic in experimental animals [33] and humans [34].
Here we show that increased bile tolerance can signifi-
cantly impact on survival and colonisation. It is likely that
enhanced persistence will also enhance efficacy in thera-
peutic models. Indeed, in support of this we demonstrate
that bifidobacteria with increased bile tolerance are capa-
ble of reducing oral infection with L. monocytogenes.
Whilst the levels of enhanced protection are low (<1 log
reduction in Listerial invasion of internal organs relative to
mice administered the wild-type) they are statistically sig-
nificant.
We recently demonstrated that cloning and expression of
the betaine uptake system BetL in B. breve UCC2003 can
Improved clinical efficacy Figure 6
Improved clinical efficacy. Probiotic dosing of BALB/c 
mice with Bifidobacterium breve bilE+ (black) reduces the level 
of subsequent Listeria monocytogenes infection. Bacterial 
growth was followed in (A) the liver and (B) the spleen 3 
days post infection.BMC Microbiology 2008, 8:176 http://www.biomedcentral.com/1471-2180/8/176
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significantly enhance acid and salt tolerance of the engi-
neered strain and promote survival in the mouse GI tract
[21]. We determined moderately higher rates of survival in
vivo when strains are engineered to enhance bile tolerance.
Indeed, we find greater colonisation of the small intestine
through enhanced bile tolerance of B. breve, a finding that
may have significant biomedical consequences since the
small intestine is the key site of immune sampling in the
GI tract. In addition, we have extended the earlier study to
demonstrate an application in the GRAS organism L. lac-
tis. This is particularly significant given that L. lactis heter-
ologously expressing the cytokine IL-10 locally within the
gut in murine models of IBD have previously been shown
to alleviate symptoms of gastrointestinal inflammation
[8]. Thus, any attempt to increase the GIT persistence of
this strain may be important for the future development
of novel vaccine and drug delivery systems. Collectively
this work outlines the application of the patho-biotech-
nology concept to enhance the robustness and efficacy of
potential probiotic organisms. Whilst this approach is
unlikely to gain immediate acceptance by regulatory bod-
ies given the genetically modified nature of the con-
structed strains, we propose that this work represents a
further proof-of-concept that may inform future studies to
enhance delivery of live organisms, vaccines or biothera-
peutic agents to the GI tract [35,36].
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